LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Pulmonx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.75−0.03 (-1.69%)
Close on Oct 19, 2026
- Market cap
- $74.32M
- P/E (TTM)
- –
- Dividend yield
- –
Pulmonx Corp revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $55.50M | $56.06M | $57.02M | $58.80M | $58.67M | $57.82M | $56.47M | $54.31M | $52.31M | $49.45M | $45.92M | $41.65M | 63.5% | -5.4% |
| EMEA | $28.80M | $28.07M | $26.99M | $25.23M | $23.74M | $22.70M | $22.33M | $20.85M | $20.57M | $19.92M | $19.34M | $19.82M | 32.9% | +21.4% |
| Asia Pacific | $2.84M | $4.14M | $6.23M | $7.33M | $7.76M | $6.54M | $4.44M | $3.60M | $3.14M | $3.13M | $3.02M | $2.99M | 3.2% | -63.4% |
| Other International | $297.00K | $273.00K | $260.00K | $309.00K | $386.00K | $423.00K | $556.00K | $551.00K | $570.00K | $499.00K | $399.00K | $360.00K | 0.3% | -23.1% |
From the segment and revenue-disaggregation notes of Pulmonx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.